Therapeutic approach for neuronal disease by regulating reninangiotensin system

Current Hypertension Reviews

Volumn 9, Issue 2, 2013, Pages 99-107

  Ohshima, Kousei ^a   Mogi, Masaki ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer disease; Angiotensin II; Life style related disorder; Multiple sclerosis; Muscular dystrophy; Neuroinflammation; Parkinson disease; Stroke

Indexed keywords

CANDESARTAN; CAPTOPRIL; CHOLESTEROL; EPROSARTAN; LOSARTAN; NITRENDIPINE; TRIACYLGLYCEROL; VALSARTAN;

ALZHEIMER DISEASE; ARTICLE; BODY MASS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; DEMENTIA; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DUCHENNE MUSCULAR DYSTROPHY; HOMEOSTASIS; HUMAN; HYPERTENSION; LIFESTYLE; MORTALITY; MULTIPLE SCLEROSIS; MUSCULAR DYSTROPHY; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; SKINFOLD THICKNESS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; HUMANS; NERVOUS SYSTEM DISEASES; RENIN-ANGIOTENSIN SYSTEM;

EID: 84881536152     PISSN: 15734021     EISSN: 18756506     Source Type: Journal    
DOI: 10.2174/15734021113099990004     Document Type: Article

References (107)

1. Bader M, Ganten D. Update on tissue renin-angiotensin systems. J Mol Med 2008; 86: 615-621.
2. Johren O, Imboden H, Hauser W, Maye I, Sanvitto GL, Saavedra JM. Localization of angiotensin-converting enzyme, angiotensin II, angiotensin II receptor subtypes, and vasopressin in the mouse hypothalamus. Brain Res 1997; 757: 218-227.
3. Saavedra JM. Brain angiotensin II: New developments, unanswered questions and therapeutic opportunities. Cell Mol Neurobiol 2005; 25: 485-512.
4. Phillips MI. Functions of angiotensin in the central nervous system. Annu Rev Physiol 1987; 49: 413-435.
5. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: A workshop consensus statement. Am Heart J 1991;121:1244-1263.
6. von Bohlen und Halbach O, Albrecht D. The CNS reninangiotensin system. Cell Tissue Res 2006; 26: 599-616.
7. Phillips MI, de Oliveira EM. Brain renin angiotensin in disease. J Mol Med 2008; 86: 715-722.
8. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010; 140:918-934.
9. Infante-Duarte C, Waiczies S, Wuerfel J, Zipp F. New developments in understanding and treating neuroinflammation. J Mol Med 2008; 86: 975-985.
10. Ownby RL. Neuroinflammation and cognitive aging. Curr Psychiatry Rep 2010; 12: 39-45.
11. Platten M, Youssef S, Hur EM, et al. Blocking angiotensinconverting enzyme induces potent regulatory T cells and modulates Th1-and Th17-mediated autoimmunity. Proc Natl Acad Sci U S A 2009; 106: 14948-14953.
12. Lanz TV, Ding Z, Ho PP, et al. Angiotensin II sustains brain inflammation in mice via tgf-beta. J Clin Invest 2010; 120: 2782-2794.
13. de Kloet AD, Krause EG, Woods SC. The renin angiotensin system and the metabolic syndrome. Physiol Behav 2010; 100: 525-534.
14. Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein e epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for latelife Alzheimer disease. Ann Intern Med 2002; 137: 149-155.
15. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. BMJ 2001; 322: 1447-1451.
16. Kivipelto M, Ngandu T, Fratiglioni L, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005; 62:1556-1560.
17. Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: The Honolulu-Asia aging study. Neurobiol Aging 2000;21: 49-55.
18. Li G, Rhew IC, Shofer JB, et al. Age-varying association between blood pressure and risk of dementia in those aged 65 and older: A community-based prospective cohort study. J Am Geriatr Soc. 2007; 55: 1161-1167.
19. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005; 65: 545-551.
20. Ninomiya T, Ohara T, Hirakawa Y, et al. Midlife and late-life blood pressure and dementia in Japanese elderly: The Hisayama study. Hypertension 2011; 58: 22-28.
21. Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y, Mayeux R. The relationship of hypertension in the elderly to ad, vascular dementia, and cognitive function. Neurology 2002; 58:1175-1181.
22. Qiu C, Hu G, Kivipelto M, et al. Association of blood pressure and hypertension with the risk of Parkinson disease: The National Finrisk study. Hypertension 2011; 57: 1094-1100.
23. Qiu C, von Strauss E, Fastbom J, Winblad B, Fratiglioni L. Low blood pressure and risk of dementia in the Kungsholmen project: A 6-year follow-up study. Arch Neurol 2003; 60: 223-228.
24. Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007; 69: 1688-1695.
25. Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J. Total cholesterol and the risk of Parkinson disease. Neurology 2008; 70: 1972-1979.
26. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum cholesterol levels and the risk of Parkinson's disease. Am J Epidemiol 2006; 164: 998-1002.
27. Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW. Low LDL cholesterol and increased risk of Parkinson's disease: Prospective results from Honolulu-Asia aging study. Mov Disord 2008; 23: 1013-1018.
28. Grandinetti A, Morens DM, Reed D, MacEachern D. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol 1994; 139: 1129-1138.
29. Tan ZS, Seshadri S, Beiser A, et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: The Framingham study. Arch Intern Med 2003; 163: 1053-1057.
30. Mielke MM, Zandi PP, Shao H, et al. The 32-year relationship between cholesterol and dementia from midlife to late life. Neurology 2010; 75: 1888-1895.
31. Driver JA, Smith A, Buring JE, Gaziano JM, Kurth T, Logroscino G. Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2008; 31: 2003-2005.
32. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61:661-666.
33. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia aging study. Diabetes 2002; 51: 1256-1262.
34. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001;154: 635-641.
35. Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia: The Rotterdam study. Neurology 1999; 53: 1937-1942.
36. Curb JD, Rodriguez BL, Abbott RD, et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 1999; 52: 971-975.
37. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004; 63:1181-1186.
38. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2007; 30: 842-847.
39. Xu Q, Park Y, Huang X, et al. Diabetes and risk of Parkinson's disease. Diabetes Care 2011; 34: 910-915.
40. Kalmijn S, Foley D, White L, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol 2000; 20: 2255-2260.
41. Forti P, Pisacane N, Rietti E, et al. Metabolic syndrome and risk of dementia in older adults. J Am Geriatr Soc 2010; 58: 487-492.
42. Raffaitin C, Gin H, Empana JP, et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: The Three-City study. Diabetes Care 2009; 32: 169-174.
43. Vanhanen M, Koivisto K, Moilanen L, et al. Association of metabolic syndrome with Alzheimer disease: A population-based study. Neurology 2006; 67: 843-847.
44. Yaffe K, Kanaya A, Lindquist K, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004; 292: 2237-2242.
45. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry 2010; 67: 505-512.
46. Power MC, Weuve J, Gagne JJ, et al. The association between blood pressure and incident Alzheimer disease: A systematic review and meta-analysis. Epidemiology 2011; 22: 646-659.
47. Guan JW, Huang CQ, Li YH, et al. No association between hypertension and risk for Alzheimer's disease: A meta-analysis of longitudinal studies. J Alzheimers Dis 2011; 27(4): 799-807.
48. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International Union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-472.
49. Reinecke K, Lucius R, Reinecke A, Rickert U, Herdegen T, Unger T. Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: Role of the AT2 receptor and the transcription factor NF-kappa. FASEB J 2003; 17: 2094-2096.
50. Li J, Culman J, Hortnagl H, et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005; 19: 617-619.
51. Gendron L, Laflamme L, Rivard N, Asselin C, Payet MD, Gallo-Payet N. Signals from the AT2 (angiotensin type 2) receptor of angiotensin II inhibit p21ras and activate mapk (mitogen-activated protein kinase) to induce morphological neuronal differentiation in NG108-15 cells. Mol Endocrinol 1999; 13: 1615-1626.
52. Cote F, Laflamme L, Payet MD, Gallo-Payet N. Nitric oxide, a new second messenger involved in the action of angiotensin II on neuronal differentiation of NG108-15 cells. Endocr Res 1998; 24: 403-407.
53. Cote F, Do TH, Laflamme L, Gallo JM, Gallo-Payet N. Activation of the AT(2) receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum. J Biol Chem 1999; 274: 31686-31692.
54. Mogi M, Li JM, Iwanami J, et al. Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 2006; 48: 141-148.
55. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
56. Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-1226.
57. Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): A randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431-1439.
58. Schrader J, Luders S, Kulschewski A, et al. The ACCESS study: Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34: 1699-1703.
59. Abuissa H, Jones PG, Marso SP, O'Keefe JH, Jr. Angiotensinconverting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46: 821-826.
60. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: A systematic review and meta-analysis. Am J Ther 2008; 15: 36-43.
61. Inaba S, Iwai M, Tomono Y, et al. Exaggeration of focal cerebral ischemia in transgenic mice carrying human renin and human angiotensinogen genes. Stroke 2009; 40: 597-603.
62. Iwai M, Liu HW, Chen R, et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004; 110: 843-848.
63. Iwanami J, Mogi M, Tsukuda K, et al. Effect of angiotensin II type 2 receptor deletion in hematopoietic cells on brain ischemiareperfusion injury. Hypertension 2011; 58: 404-409.
64. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685-1697.
65. Li JM, Mogi M, Iwanami J, et al. Temporary pretreatment with the angiotensin II type 1 receptor blocker, valsartan, prevents ischemic brain damage through an increase in capillary density. Stroke 2008; 39: 2029-2036.
66. Langa KM, Chernew ME, Kabeto MU, et al. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J Gen Intern Med 2001; 16: 770-778.
67. Zhu CW, Sano M. Economic considerations in the management of Alzheimer's disease. Clin Interv Aging 2006; 1: 143-154.
68. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: A Delphi consensus study. Lancet 2005; 366: 2112-2117.
69. Kalaria RN, Maestre GE, Arizaga R, et al. Alzheimer's disease and vascular dementia in developing countries: Prevalence, management, and risk factors. Lancet Neurol 2008; 7: 812-826.
70. Wang J, Ho L, Chen L, et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007; 117: 3393-3402.
71. Hu J, Igarashi A, Kamata M, Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards a beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 2001; 276: 47863-47868.
72. Ohrui T, Tomita N, Sato-Nakagawa T, et al. Effects of brainpenetrating ace inhibitors on Alzheimer disease progression. Neurology 2004; 63: 1324-1325.
73. Ohrui T, Matsui T, Yamaya M, et al. Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc 2004; 52: 649-650.
74. Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 2007; 6: 373-378.
75. Wolozin B, Lee A, Lee A, Whitmer R, Kazis L. Use of angiotensin receptor blockers is associated with a lower incidence and progression of Alzheimer's disease Alzheimer's and Dementia. 2008; 4: T118.
76. Mogi M, Li JM, Tsukuda K, et al. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun 2008; 375: 446-449.
77. Tsukuda K, Mogi M, Iwanami J, et al. Cognitive deficit in amyloid beta-injected mice was improved by pretreatment with a low dose of telmisartan partly due to PPAR-gamma activation. Hypertension 2009.
78. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
79. Morley JF, Hurtig HI. Current understanding and management of Parkinson disease: Five new things. Neurology 2010; 75: S9-15.
80. Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Prog Neurobiol 2005; 76: 77-98.
81. Andersen JK. Oxidative stress in neurodegeneration: Cause or consequence? Nat Med 2004; 10 Suppl: S18-25.
82. Valenzuela R, Barroso-Chinea P, Villar-Cheda B, et al. Location of prorenin receptors in primate substantia nigra: Effects on dopaminergic cell death. J Neuropathol Exp Neurol 2010; 69: 1130-1142.
83. Ge J, Barnes NM. Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders. Eur J Pharmacol 1996; 297: 299-306.
84. Allen AM, MacGregor DP, Chai SY, et al. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Ann Neurol 1992; 32: 339-344.
85. Brown DC, Steward LJ, Ge J, Barnes NM. Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Br J Pharmacol 1996; 118: 414-420.
86. Mendelsohn FA, Jenkins TA, Berkovic SF. Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats. Brain Res 1993; 613: 221-229.
87. Jenkins TA, Mendelsohn FA, Chai SY. Angiotensin-converting enzyme modulates dopamine turnover in the striatum. J Neurochem 1997; 68: 1304-1311.
88. Lopez-Real A, Rey P, Soto-Otero R, Mendez-Alvarez E, Labandeira-Garcia JL. Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of parkinsonism. J Neurosci Res 2005; 81: 865-873.
89. Munoz A, Rey P, Guerra MJ, Mendez-Alvarez E, Soto-Otero R, Labandeira-Garcia JL. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology 2006; 51: 112-120.
90. Kurosaki R, Muramatsu Y, Kato H, et al. Effect of angiotensinconverting enzyme inhibitor perindopril on interneurons in MPTPtreated mice. Eur Neuropsychopharmacol 2005; 15: 57-67.
91. Jenkins TA, Wong JY, Howells DW, Mendelsohn FA, Chai SY. Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in the MPTP-treated mouse. J Neurochem 1999; 73: 214-219
92. Becker C, Jick SS, Meier CR. Use of antihypertensives and the risk of Parkinson disease. Neurology 2008; 70: 1438-1444.
93. Shao J, Nangaku M, Miyata T, et al. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 2003; 42: 31-38.
94. Constantinescu CS, Ventura E, Hilliard B, Rostami A. Effects of the angiotensin converting enzyme inhibitor captopril on experimental autoimmune encephalomyelitis. Immunopharmacol Immunotoxicol 1995; 17: 471-491.
95. Li JM, Mogi M, Tsukuda K, et al. Angiotensin II-induced neural differentiation via angiotensin ii type 2 (AT2) receptor-MMS2 cascade involving interaction between AT2 receptor-interacting protein and src homology 2 domain-containing protein-tyrosine phosphatase 1. Mol Endocrinol 2007; 21: 499-511.
96. Kawajiri M, Mogi M, Osoegawa M, et al. Reduction of angiotensin II in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler 2008; 14: 557-560.
97. Stegbauer J, Lee DH, Seubert S, et al. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci USA 2009; 106: 14942-14947.
98. Jefferies JL, Eidem BW, Belmont JW, et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 2005; 112: 2799-2804.
99. Duboc D, Meune C, Pierre B, et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J 2007; 154: 596-602.
100. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Becane HM. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005; 45: 855-857.
101. Li Y, Foster W, Deasy BM, Chan Y, Prisk V, Tang Y, et al. Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: A key event in muscle fibrogenesis. Am J Pathol 2004; 164: 007-1019.
102. Olson EN, Sternberg E, Hu JS, Spizz G, Wilcox C. Regulation of myogenic differentiation by type beta transforming growth factor. J Cell Biol 1986;103: 1799-1805.
103. Charge SB, Rudnicki MA. Cellular and molecular regulation of muscle regeneration. Physiol Rev 2004; 84: 209-238
104. Gosselin LE, Williams JE, Deering M, Brazeau D, Koury S, Martinez DA. Localization and early time course of TGF-beta 1 mrna expression in dystrophic muscle. Muscle Nerve 2004; 30: 645-653.
105. Sato K, Li Y, Foster W, et al. Improvement of muscle healing through enhancement of muscle regeneration and prevention of fibrosis. Muscle Nerve 2003; 28: 365-372.
106. Cohn RD, van Erp C, Habashi JP, et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007; 13: 204-210.
107. Sun G, Haginoya K, Dai H, et al. Intramuscular renin-angiotensin system is activated in human muscular dystrophy. J Neurol Sci 2009; 280: 40-48.